Cargando…
Severe Esophagitis and Gastritis from Nivolumab Therapy
Nivolumab is a novel chemotherapy currently approved for the treatment of multiple metastatic malignancies. This class of therapy, known as immune checkpoint inhibitors, is notable for an autoimmune-related adverse event profile. Diarrhea and colitis are common gastrointestinal adverse events, howev...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American College of Gastroenterology
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404341/ https://www.ncbi.nlm.nih.gov/pubmed/28459081 http://dx.doi.org/10.14309/crj.2017.57 |